LINGBAO GOLD (03330) announces profit joy, with an estimated net profit of approximately 1.503 billion to 1.573 billion yuan in 2025, an increase of approximately 115% to 125% year-on-year.
Lingbao Gold (03330) announced that the group expects to achieve revenue between approximately RMB 12.935 billion and RMB 13.172 billion for the year ending December 31, 2025, an increase of about 9% to 11% year-on-year; and a net profit of approximately RMB 1.503 billion to RMB 1.573 billion for the year 2025, a year-on-year increase of about 115% to 125%.
LINGBAO GOLD (03330) announced that the group is expected to achieve revenue between approximately RMB 12.935 billion and RMB 13.172 billion for the year ending December 31, 2025, representing an increase of approximately 9% to 11% compared to the previous year. The net profit for the year 2025 is expected to be between approximately RMB 1.503 billion and RMB 1.573 billion, an increase of approximately 115% to 125% compared to the previous year. Based on current available information, the increase in revenue and net profit is mainly attributed to the group's continuous optimization of production organization, strengthening of production scheduling, maintaining a stable production pace, resulting in a continuous increase in gold production compared to the previous year. The group also continues to implement cost reduction and efficiency improvement measures rigorously, leading to a sustained improvement in operational efficiency. Combined with the favorable factors of rising gold market prices, the overall performance of the group has significantly improved.
Related Articles

R&F Properties (02777) total sales revenue in 2025 is expected to be approximately 14.21 billion yuan, a year-on-year increase of 26.54%.

Shanghai Pharmaceuticals Holding (601607.SH): The oral solution of bromhexine hydrochloride has obtained production approval.

ZHONG JIA GX (00899) issued 297 million shares by way of a 1-for-2 rights issue.
R&F Properties (02777) total sales revenue in 2025 is expected to be approximately 14.21 billion yuan, a year-on-year increase of 26.54%.

Shanghai Pharmaceuticals Holding (601607.SH): The oral solution of bromhexine hydrochloride has obtained production approval.

ZHONG JIA GX (00899) issued 297 million shares by way of a 1-for-2 rights issue.

RECOMMEND

Bank Of America Sees Three Drivers Supporting Chinese Consumer Stocks: Low Base, Deep Undervaluation, And Convertible‑Like Defensive Traits
07/01/2026

Cross‑Border E‑Commerce In 2025: Tariffs, Trade Wars, And Shifting Away From The United States
07/01/2026

Asian Stock Markets Record The Strongest Annual Start Ever As Shanghai Composite Hits Multi‑Year High And Sets Longest Winning Streak; Japan And Korea Rally
07/01/2026


